Get the Stockscreener App
7.95
0.50%
-0.04
After Hours:
7.95
Xeris Biopharma Holdings Inc stock is traded at $7.95, with a volume of 1.54M.
It is down -0.50% in the last 24 hours and up +6.14% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.99
Open:
$7.94
24h Volume:
1.54M
Relative Volume:
0.66
Market Cap:
$1.28B
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-18.93
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-2.21%
1M Performance:
+6.14%
6M Performance:
+91.11%
1Y Performance:
+173.20%
1-Day Range:
$7.775
$8.095
1-Week Range:
$7.775
$8.46
52-Week Range:
$2.82
$8.505
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.95 | 1.29B | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Can Xeris Biopharma Holdings Inc. stock weather global recessionLayoff News & Community Verified Watchlist Alerts - newser.com
When is the best time to exit Xeris Biopharma Holdings Inc.Weekly Trade Recap & Accurate Trade Setup Notifications - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com
Xeris Biopharma Holdings Inc. stock momentum explained2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Xeris Biopharma Holdings Inc. stock prediction for this weekDay Trade & Weekly Top Stock Performers List - newser.com
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus - Yahoo Finance
How to read the order book for Xeris Biopharma Holdings Inc.Bear Alert & Safe Entry Point Identification - newser.com
Risk vs reward if holding onto Xeris Biopharma Holdings Inc.2025 Top Decliners & Reliable Entry Point Alerts - newser.com
Quantitative breakdown of Xeris Biopharma Holdings Inc. recent moveWatch List & Verified Short-Term Plans - newser.com
Can Xeris Biopharma Holdings Inc. recover in the next quarter2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Volume spikes in Xeris Biopharma Holdings Inc. stock – what they meanJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
What is the fair value estimate for Xeris Biopharma Holdings Inc. (2B30) stock in 2025Weekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Analyzing net buyer seller activity in Xeris Biopharma Holdings Inc.IPO Watch & Reliable Intraday Trade Plans - newser.com
Is it time to cut losses on Xeris Biopharma Holdings Inc.2025 Key Highlights & Community Verified Trade Alerts - newser.com
Measuring Xeris Biopharma Holdings Inc.’s beta against major indicesTrade Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
How buyback programs support Xeris Biopharma Holdings Inc. (2B30) stock2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Xeris Biopharma (NASDAQ:XERS) - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 4%Here's What Happened - MarketBeat
Xeris Biopharma Holdings (XERS): Exploring Valuation as Analysts Grow Bullish on Breakeven Prospects and Earnings Progress - simplywall.st
Xeris Biopharma Reaches New 52-Week High of $8.51, Up 253% - Markets Mojo
News impact scoring models applied to Xeris Biopharma Holdings Inc.Portfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Xeris Biopharma Holdings Inc.’s volatility index tracking explainedMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Will Xeris Biopharma Holdings Inc. outperform the marketJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Will Xeris Biopharma Holdings Inc. stock deliver shareholder valueJuly 2025 Market Mood & Low Drawdown Momentum Ideas - newser.com
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
XERS Back In The Spotlight As Recorlev Surges, Gvoke Steadies, And Keveyis Holds Strong - RTTNews
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma's Path Toward Profitability Might Change The Case For Investing In XERS - simplywall.st
Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? - sharewise.com
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic? - Yahoo Finance
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Why Xeris Biopharma Holdings Inc. stock could be next big winnerQuarterly Earnings Summary & Detailed Earnings Play Strategies - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could outperform next yearMarket Movement Recap & AI Enhanced Trading Signals - newser.com
Published on: 2025-10-03 05:03:07 - newser.com
Leading vs lagging indicators on Xeris Biopharma Holdings Inc. performanceWeekly Profit Summary & Risk Managed Investment Strategies - newser.com
Oklahoma City NewsThe Oklahoman - FinancialContent
Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsJobs Report & Free Accurate Trade Setup Notifications - newser.com
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):